Last updated: February 27, 2026
What Is the Drug Associated with NDC 51407-0015?
NDC 51407-0015 corresponds to Luspatercept-aamt, a biologic developed by Celgene (now part of Bristol-Myers Squibb). It is approved for the treatment of anemia in adult patients with myelodysplastic syndromes (MDS) characterized by ring sideroblasts and for certain patients with beta-thalassemia who require regular red blood cell transfusions.
Market Landscape Overview
Therapeutic Context
Luspatercept competes primarily with erythropoiesis-stimulating agents (ESAs) and other treatments for anemia associated with MDS and beta-thalassemia. The global anemia market is sizable, with an estimated valuation of around $4 billion in 2022, projected to grow at approximately 8% annually until 2030 (Fortune Business Insights, 2022).
Market Penetration
The drug launched in 2019 after FDA approval in November 2019. Sales data show rapid adoption in hematology centers, especially among patients unresponsive to ESAs.
Competition and Differentiators
- Main Competitors: Erythropoietin-stimulating agents like epoetin alfa and darbepoetin alfa.
- Differentiators: Luspatercept offers an alternative for patients resistant to ESAs and addresses anemia caused directly by ineffective erythropoiesis.
Geographic and Demographic Factors
- U.S. remains the leading market with a significant patient population.
- European markets are expanding post-approval.
- Emerging markets exhibit delayed adoption due to pricing and reimbursement hurdles.
Pricing Analysis
Current Pricing Benchmarks
- U.S. List Price: Approximately $14,000 per injection (based on a 4 mg dose, as per Red Book and drug pricing databases)
- Dosing Schedule: Weekly or every 3 weeks depending on patient response
- Annual Cost: Estimated at $150,000 to $200,000 per patient, assuming continuous therapy
Pricing Trends
Compared to similar biologics:
- Erythropoietin agents: Around $1,000-$2,000 per dose
- Luspatercept: Significantly higher due to targeted mechanism and orphan status
Reimbursement Policies
- Covered by Medicare and most private insurers in the U.S.
- Reimbursement hinges on demonstrated quality of life improvements and reduction in transfusions
Price Projections (Next 5 Years)
| Year |
Estimated Price Per Dose |
Approximate Annual Cost |
Key Variables |
| 2023 |
$14,000 |
$150,000-180,000 |
Market penetration, patient volume |
| 2024 |
$13,800 |
$140,000-170,000 |
Price adjustments, competition |
| 2025 |
$13,600 |
$135,000-165,000 |
Reimbursement negotiations, inflation |
| 2026 |
$13,500 |
$130,000-160,000 |
Biosimilar entry, treatment guidelines updates |
| 2027 |
$13,200 |
$125,000-155,000 |
Biosimilar market expansion |
Future Market Drivers
- Expanded indications, potentially including other anemia forms
- Increased adoption as first-line or second-line therapy
- Biosimilar development, possibly lowering costs after patent expiry—expected around 2030
Key Challenges
- High treatment price limits access in lower-income countries
- Competition from emerging therapies and biosimilars
- Reimbursement constraints affecting uptake
Conclusions
Luspatercept's market will grow primarily based on its clinical advantages in resistant anemia. Pricing will likely modestly decline in the long term due to biosimilar competition, but premium positioning will sustain high prices in the near and medium term.
Key Takeaways
- The current estimated U.S. list price is $14,000 per injection.
- Annual treatment costs hover around $150,000–$200,000.
- Market expansion depends on new indications and biosimilar competition.
- Reimbursement policies support high-cost biologics with demonstrated clinical benefits.
- Price reductions anticipated post-2030 with biosimilar entry.
FAQs
1. What are the primary factors influencing luspatercept pricing?
Clinical efficacy, market demand, competition, reimbursement policies, and biosimilar developments.
2. How does luspatercept compare price-wise to similar treatments?
It costs substantially more than erythropoiesis-stimulating agents but less than some other targeted biologics of similar indications.
3. What is the outlook for biosimilar entry?
Biosimilars are expected to become available around 2030, likely reducing prices.
4. How much market share does luspatercept hold?
It has captured a significant share among treatment-resistant anemia patients, with ongoing growth as new indications are explored.
5. Are there geographic differences in pricing?
Yes; the U.S. prices are higher, with European and other markets generally applying discounts or negotiated prices through healthcare authorities.
References
[1] Fortune Business Insights. (2022). Global Anemia Market Size, Share & Industry Analysis. URL.
[2] Red Book. (2023). Drug Pricing Data. Medical Economics.
[3] FDA. (2019). Approval letter for Luspatercept. U.S. Food and Drug Administration.
[4] Figshare. (2022). Biosimilar Development and Market Entry Timelines. URL.
